Boryung Biopharma

Trivalent influenza vaccine with A (H1N1, H3N2) and B (Victoria) antigens; when it was re-approved in May 2025 production moved from a contract manufacturer to the company itself.

Hepatitis A vaccine developed with cell culture; approved in December 2020 and launched in March 2022. In March 2025 its approved age range was widened to children aged 24 months to 15 years.

Single-dose influenza antiviral candidate that inhibits cap-dependent endonuclease, in-licensed for Korea on an exclusive basis from Taiwan's TaiGen; the Korean phase 3 trial plan was approved in August 2026.

Won the 2026-2027 season procurement for the Moderna COVID-19 vaccine (1.93 million doses) and delivers directly to about 15,000 public health centres and contracted clinics.

Signed an exclusive Korean commercialization licence with Taiwan's TaiGen for the single-dose influenza antiviral BRC-201 (TG-1000), and filed the phase 3 trial plan two months later, in April 2026.

Won the 2026-2027 season procurement for the Moderna COVID-19 vaccine (1.93 million doses in total) at KRW 103.255 billion; the contract runs to 31 August 2027, with phased deliveries from 2 October 2026.

Received approval from the Ministry of Food and Drug Safety for the BRC-201 phase 3 trial plan, which will enrol 284 adult and adolescent patients with uncomplicated acute influenza and measure time to symptom relief.